Gen-Probe, BioMerieux Pen Three Technology Agreements | GenomeWeb

NEW YORK, Oct. 7 (GenomeWeb News) - Gen-Probe and BioMerieux have signed three agreements in which Gen-Probe will pay for access to BioMerieux's blood clot-related biomarkers for blood clotting disorders, Gen-Probe will gain negotiation rights for access to the BioMerieux Nuclisens EasyQ platform, and BioMerieux will have access to Gen-Probe's ribosomal RNA markers, said BioMerieux in a statement today.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.